Novo-Nordisk A/S (NVO)
Health Care
Novo-Nordisk A/S (NVO) is listed on the New York Stock Exchange, where its shares have traded since April 30, 1981. SentiSense covers Novo-Nordisk A/S in the Health Care sector. Maziar Mike Doustdar is its chief executive officer. The company reports 69,500 employees, and its corporate website is www.novonordisk.com.
About Novo-Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Latest reported results
Novo Nordisk A/S reported revenue of 78.68 billion DKK for Q3 FY2026, up 4.9% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 1,337 institutions reported holding NVO, with 325.7 million shares worth $15.6 billion in aggregate. The largest reported holders were Dodge & Cox, Loomis Sayles & Co L P and Capital Group. Of the 5 largest reported holders, 3 added shares and 2 reduced their positions during the quarter.
More on NVO
- NVO sentiment: whether news and social coverage of Novo-Nordisk A/S leans bullish or bearish, and the stories driving it.
- NVO ownership: all 1,337 reporting institutions, plus insider and congressional trades.
- NVO financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Novo-Nordisk A/S: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Novo-Nordisk A/S do?
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products.
What sector is NVO in?
SentiSense classifies Novo-Nordisk A/S in the Health Care sector.
Where does NVO stock trade?
Novo-Nordisk A/S (NVO) is listed on the New York Stock Exchange, where its shares have traded since April 30, 1981.
Who is the CEO of Novo-Nordisk A/S?
Maziar Mike Doustdar is the chief executive officer of Novo-Nordisk A/S.